Amgen Avoids Supreme Court Review of Patents on Enbrel Drug
- Supreme Court rebuffs petition filed by Novartis’s Sandoz
- Amgen patents blocks generic arthritis drug until 2029
This article is for subscribers only.
The Supreme Court turned away a petition that sought to challenge two Amgen Inc. patents on the top-selling rheumatoid arthritis drug Enbrel, ensuring Novartis AG’s Sandoz unit won’t be able to sell a biosimilar of the drug in the U.S. until 2029.
The justices declined to hear arguments by Sandoz, which claims an appeals court erred in upholding the two Amgen patents that prevent it from entering the U.S. market. Sandoz got regulatory approval in 2016 to sell a copycat version that it calls Erelzi and the patents are the only thing standing in its way.